A First-In-Human Study of LY3985297 in Healthy Participants - Trial NCT06395012
Access comprehensive clinical trial information for NCT06395012 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 153 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company
Timeline & Enrollment
Phase 1
May 01, 2024
Jul 01, 2025
Primary Outcome
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
Summary
The main purpose of this study is to see if LY3985297, the study drug, is safe and
 well-tolerated when given as a single dose or as multiple doses either through an intravenous
 (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study
 will also evaluate how much of the study drug LY3985297 gets into the blood stream and how
 long it takes the body to remove it.
 
 The study is conducted in two parts (part A and B), each part has a separate treatment
 cohort.
 
 The study will last up to approximately 116 days for part A, and 145 days for part B,
 including the screening period.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06395012
Non-Device Trial